Medifocus Inc. Announces, Its Company Information Has Been Accepted To Be Available Through Standard & Poor’s Market Access Program, A Recognized Securities Manual for Secondary Trading in up to 38 States under their Blue Sky Laws

COLUMBIA, Md.--()--Medifocus Inc. (OTC:MDFZF.PK and TSXV:MFS) a medical device company currently in Phase III clinical studies for the treatment of Breast Cancer, is pleased to announce that its company information will be made available via Standard & Poor's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have their company information disseminated to users of Standard & Poor's Advisor Insight. The company information to be made available through this program includes share price, volume, dividends, shares outstanding, company financial position, and earnings. Standard & Poor's Advisor Insight is an Internet-based research engine used by more than 100,000 investment advisors. A public version of the site is available at www.advisorinsight.com.

In addition, information about companies in Standard & Poor's Market Access Program will be available via S&P's Stock Guide database, which is distributed electronically to virtually all major quote vendors. As part of the program, a full description of Medifocus Inc. will also be published in the Daily News section of Standard Corporation Records, a recognized securities manual for secondary trading in up to 38 states under their Blue Sky Laws.

About Medifocus Inc.

Medifocus is a medical device company which owns a patented microwave focusing technology platform, the Adaptive Phased Array ("APA") system, which can precisely target and concentrate microwave energy to destroy cancer tumors without damaging healthy tissue when used alone or in conjunction with chemotherapy or radiation. The ability to target tumors with a precision controlled dose of heat can be used to destroy tumors at higher temperatures, to treat tumors in combination with chemotherapy and/or radiation at moderate temperatures for increased effectiveness over those treatments alone. The core technology has been exclusively licensed from the Massachusetts Institute of Technology (MIT). Medifocus has completed the development of a dedicated cancer treatment system for the treatment of breast cancer. Medifocus has received approval from both the USA FDA and Health Canada to begin it’s Pivotal Phase III Clinical Study.

Company information distributed through the Market Access Program is based upon information that Standard & Poor’s considers to be reliable, but neither Standard & Poor’s nor its affiliates warrant its completeness or accuracy, and it should not be relied upon as such. This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument.

Contacts

Medifocus Inc.
John Mon, COO
410-290-5734
jmon@medifocususa.com
or
Standard and Poor’s Customer Contact:
Richard Albanese
212-438-3647
richard_albanese@standardandpoors.com
or
Standard and Poor’s Media Relations Contact:
Michael Privitera
212-438-6679
michael_privitera@standardandpoors.com

Sharing

Contacts

Medifocus Inc.
John Mon, COO
410-290-5734
jmon@medifocususa.com
or
Standard and Poor’s Customer Contact:
Richard Albanese
212-438-3647
richard_albanese@standardandpoors.com
or
Standard and Poor’s Media Relations Contact:
Michael Privitera
212-438-6679
michael_privitera@standardandpoors.com